Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ping Mao

Showing results (531-540 of 565) with videos related to

Pageof 57
Sort By:
The Lancet. Oncology|February 12, 2018
Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort studyXin-Ran Tang, Ying-Qin Li, Shao-Bo Liang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2026
Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER TrialsSai-Wei Huang, Ye-Lin Liang, Ya-Lan Tao, et al.
Radiology|August 26, 2025
MRI-based Middle Neck Involvement in Stage N1-N2 Nasopharyngeal Carcinoma: A Marker for Risk StratificationGuan-Jie Qin, Wei Jiang, Wu-Qi Zhang, et al.
CA: a Cancer Journal for Clinicians|February 19, 2025
Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trialLing-Long Tang, Lin Chen, Gui-Qiong Xu, et al.
Nature Communications|May 31, 2022
A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinomaYe-Lin Liang, Yuan Zhang, Xi-Rong Tan, et al.
Cancer Cell|July 26, 2024
Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON studyJiawei Lv, Ling-Xin Xu, Zhi-Xuan Li, et al.
Leukemia & Lymphoma|September 16, 2015
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasmsXing-Nong Ye, Xin-Ping Zhou, Ju-Ying Wei, et al.
JAMA|August 23, 2022
Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical TrialLing-Long Tang, Rui Guo, Ning Zhang, et al.
The Lancet. Oncology|December 14, 2011
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trialLei Chen, Chao-Su Hu, Xiao-Zhong Chen, et al.
The Journal of Clinical Investigation|August 21, 2018
Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistanceKwon-Ho Song, Jae-Hoon Kim, Young-Ho Lee, et al.
Pageof 57

Showing results (531-540 of 565) with videos related to

Sort By:
Pageof 57
The Lancet. Oncology|February 12, 2018
Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort studyXin-Ran Tang, Ying-Qin Li, Shao-Bo Liang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2026
Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER TrialsSai-Wei Huang, Ye-Lin Liang, Ya-Lan Tao, et al.
Radiology|August 26, 2025
MRI-based Middle Neck Involvement in Stage N1-N2 Nasopharyngeal Carcinoma: A Marker for Risk StratificationGuan-Jie Qin, Wei Jiang, Wu-Qi Zhang, et al.
CA: a Cancer Journal for Clinicians|February 19, 2025
Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trialLing-Long Tang, Lin Chen, Gui-Qiong Xu, et al.
Nature Communications|May 31, 2022
A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinomaYe-Lin Liang, Yuan Zhang, Xi-Rong Tan, et al.
Cancer Cell|July 26, 2024
Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON studyJiawei Lv, Ling-Xin Xu, Zhi-Xuan Li, et al.
Leukemia & Lymphoma|September 16, 2015
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasmsXing-Nong Ye, Xin-Ping Zhou, Ju-Ying Wei, et al.
JAMA|August 23, 2022
Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical TrialLing-Long Tang, Rui Guo, Ning Zhang, et al.
The Lancet. Oncology|December 14, 2011
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trialLei Chen, Chao-Su Hu, Xiao-Zhong Chen, et al.
The Journal of Clinical Investigation|August 21, 2018
Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistanceKwon-Ho Song, Jae-Hoon Kim, Young-Ho Lee, et al.
Pageof 57